Compare BioNano Genomics Inc (BNGO) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Direxion Daily FTSE China Bull 3x Shares trades at $27.52. The key difference: Direxion Daily FTSE China Bull 3x Shares is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | YINN | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.92 | $56.62 |
52-Week Low | $1.09 | $21.45 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
YINN, the Direxion Daily FTSE China Bull 3x ETF, trades at $25.25, down 0.43% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral and RSI_6 suggests overbought conditions. Recent sentiment has improved with a Seeking Alpha rating upgrade from bearish to neutral, citing China's relative undervaluation and improved macro backdrop, though concerns remain about the fund's leveraged structure and value trap risks in Chinese equities.
The outlook for YINN is cautiously optimistic, driven by China's tech sector momentum and substantial government AI investment plans. However, significant risks include geopolitical tensions with the U.S., the fund's 3x leverage amplifying volatility, and ongoing regulatory uncertainties. Investors should weigh China's economic stimulus against structural challenges in the market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
